David González de Castro

4.0k total citations
59 papers, 2.2k citations indexed

About

David González de Castro is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, David González de Castro has authored 59 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 22 papers in Cancer Research and 20 papers in Molecular Biology. Recurrent topics in David González de Castro's work include Cancer Genomics and Diagnostics (20 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Treatments and Mutations (15 papers). David González de Castro is often cited by papers focused on Cancer Genomics and Diagnostics (20 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Treatments and Mutations (15 papers). David González de Castro collaborates with scholars based in United Kingdom, Spain and Sweden. David González de Castro's co-authors include Paul Workman, Bissan Al‐Lazikani, Paul A. Clarke, Andrew Wotherspoon, David Cunningham, Ian Chau, Manuel Salto‐Tellez, Andrés Cervantes, Gina Brown and Josep Tabernero and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

David González de Castro

58 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David González de Castro United Kingdom 28 1.0k 738 624 623 406 59 2.2k
Larissa V. Furtado United States 22 700 0.7× 605 0.8× 446 0.7× 569 0.9× 387 1.0× 68 2.0k
Todd Hembrough United States 25 880 0.9× 942 1.3× 524 0.8× 653 1.0× 158 0.4× 71 2.3k
Francesco Galimi Italy 24 1.2k 1.1× 1.1k 1.5× 444 0.7× 458 0.7× 346 0.9× 35 2.5k
Vincent Haddad United Kingdom 16 1.5k 1.5× 907 1.2× 1.3k 2.2× 485 0.8× 246 0.6× 36 2.9k
Alison M. Schram United States 25 1.1k 1.1× 1.1k 1.5× 862 1.4× 783 1.3× 204 0.5× 100 2.9k
Axel Wellmann Germany 30 847 0.8× 1.4k 2.0× 377 0.6× 427 0.7× 258 0.6× 66 2.7k
Ming‐Tseh Lin United States 30 1.2k 1.2× 897 1.2× 853 1.4× 736 1.2× 443 1.1× 76 3.3k
E. Lin United States 20 590 0.6× 518 0.7× 301 0.5× 270 0.4× 259 0.6× 47 1.7k
Bedia A. Barkoh United States 25 667 0.7× 1.1k 1.5× 611 1.0× 1.2k 2.0× 121 0.3× 45 2.4k
Tobias Dechow Germany 24 793 0.8× 692 0.9× 475 0.8× 318 0.5× 134 0.3× 73 2.0k

Countries citing papers authored by David González de Castro

Since Specialization
Citations

This map shows the geographic impact of David González de Castro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David González de Castro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David González de Castro more than expected).

Fields of papers citing papers by David González de Castro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David González de Castro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David González de Castro. The network helps show where David González de Castro may publish in the future.

Co-authorship network of co-authors of David González de Castro

This figure shows the co-authorship network connecting the top 25 collaborators of David González de Castro. A scholar is included among the top collaborators of David González de Castro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David González de Castro. David González de Castro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Linmiao, Karol Pál, Peter J. Stewart, et al.. (2024). Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials. Leukemia. 38(12). 2675–2684. 4 indexed citations
2.
3.
4.
García-Murillas, Isaac, Rosalind Cutts, David González de Castro, et al.. (2017). Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. British Journal of Cancer. 117(6). 876–883. 103 indexed citations
5.
Sclafani, Francesco, Ian Chau, David Cunningham, et al.. (2016). KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial. Annals of Oncology. 27. vi173–vi173. 1 indexed citations
6.
Litchfield, Kevin, Max Levy, Darshna Dudakia, et al.. (2016). Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nature Communications. 7(1). 13840–13840. 29 indexed citations
7.
Sharp, Adam, Andrew Wotherspoon, Alexandra Léary, et al.. (2015). Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Research Notes. 8(1). 688–688. 5 indexed citations
8.
Pender, Alexandra, Isaac García-Murillas, Sareena Rana, et al.. (2015). Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE. 10(9). e0139074–e0139074. 48 indexed citations
9.
Shaw, Emily, Rachel Butler, David González de Castro, et al.. (2014). A national platform for molecular diagnostics: Results of the Cancer Research U.K. Stratified Medicine Programme.. Journal of Clinical Oncology. 32(15_suppl). 11079–11079. 1 indexed citations
10.
Kapp, Joshua, Tim C. Diss, James Spicer, et al.. (2014). Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial. Journal of Clinical Pathology. 68(2). 111–118. 36 indexed citations
11.
Quesne, John Le, Mary O’Brien, Sanjay Popat, et al.. (2014). A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. Journal of Thoracic Oncology. 9(6). 769–774. 36 indexed citations
12.
Sclafani, Francesco, Amitesh Roy, David Cunningham, et al.. (2013). HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology. 24(12). 3123–3128. 30 indexed citations
13.
Sclafani, Francesco, David Cunningham, Josep Tabernero, et al.. (2013). Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients. European Journal of Cancer. 49. 3 indexed citations
14.
López‐Ríos, Fernando, Bárbara Angulo, Rebeca Martínez, et al.. (2013). Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. Journal of Clinical Pathology. 66(5). 381–385. 43 indexed citations
15.
López‐Ríos, Fernando, Bárbara Angulo, Rebeca Martínez, et al.. (2013). Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib. PLoS ONE. 8(1). e53733–e53733. 38 indexed citations
16.
17.
Moore, Andrew S., Amir Faisal, David González de Castro, et al.. (2012). Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 26(7). 1462–1470. 90 indexed citations
18.
Perkins, Géraldine, Timothy A. Yap, Lorna Pope, et al.. (2012). Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers. PLoS ONE. 7(11). e47020–e47020. 126 indexed citations
19.
Castro, David González de, Roberto Martínez, Felice Shieh, et al.. (2011). PP 28 Analytical performance and workflow comparison study of three methods for detecting KRAS mutations in formalin-fixed paraffin-embedded tissue (FFPET) specimens of colorectal cancer (CRC). European Journal of Cancer. 47. S18–S18. 1 indexed citations
20.
Morilla, Alison, David González de Castro, Ilaria Del Giudice, et al.. (2008). Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leukemia & lymphoma. 49(11). 2108–2115. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Larissa V. Furtado Breakdown of academic impact, for papers by Todd Hembrough Breakdown of academic impact, for papers by Francesco Galimi Breakdown of academic impact, for papers by Vincent Haddad Breakdown of academic impact, for papers by Alison M. Schram Breakdown of academic impact, for papers by Axel Wellmann Breakdown of academic impact, for papers by Ming‐Tseh Lin Breakdown of academic impact, for papers by E. Lin Breakdown of academic impact, for papers by Bedia A. Barkoh Breakdown of academic impact, for papers by Tobias Dechow
Rankless by CCL
2026